The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia

Southern Med Review

Volumn 5, Issue 1, 2012, Pages 6-13

  Sagwa, Evans ^a,b,c   Mantel Teeuwisse, Aukje Kaija ^b   Ruswa, Nunurai ^d   Musasa, Jean Paul ^e   Pal, Shanthi ^f   Dhliwayo, Panganai ^g   van Wyk, Brian ^a  

^a UNIVERSITY OF THE WESTERN CAPE   (South Africa)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Management Sciences for Health   (Namibia)

^d National Tuberculosis and Leprosy Programme   (Namibia)

^e Walvis Bay District Hospital   (Namibia)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

^g KNCV/TBCAP   (Namibia)

Author keywords

Adverse events; Drug resistance; Namibia; Second line drugs; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ADULT; ANEMIA; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESISTANT TUBERCULOSIS; EJACULATION DISORDER; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEARING LOSS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; NAMIBIA; NAUSEA; NEUROPATHY; NONHUMAN; OTOTOXICITY; PREVALENCE; PSYCHOSIS; RISK FACTOR; SHORT COURSE THERAPY; SIDE EFFECT; TINNITUS; TOXIC HEPATITIS; URINE; VISUAL DISORDER; VOMITING;

EID: 84864343368     PISSN: 11742704     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ministry of Health and Social Services (MoHSS). National Tuberculosis and Leprosy Programme: Second Medium Term Strategic Plan for Tuberculosis and Leprosy, 2010-2015. Windhoek: MoHSS; 2010.
2. Ministry of Health and Social Services. Report on the National HIV Sentinel Survey. Windhoek: MoHSS; October 2008.
3. Ministry of Health and Social Services. National Guidelines for the Management of Tuberculosis, Second edition. Windhoek: MoHSS; March 2006.
4. Nathanson E, Gupta R., Huamani P, Leimane AD, Pasechnikov AD, Tupasi TE, Vink K, Jaramillo E, Espinal MA. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2005; 9: 1027-33.
5. Tahaoglu K, Torun T, Sevim T, Atac GB, Kir A, Karasulu L, Ozmen I, Kapkli N.The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-4.
6. Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, Laserson KF Wells C D.Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-26.
7. Törün T, Güngör G, Özmen I, Bölükba Y, Maden E, Biçakçi B, Ataç G, Sevim T, Tahaogu K. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 1373-7
8. Cox HS, Kalon S, Allamuratova S, Sizaire V, Tigay ZN, Sabine R, Hamraev AK, Kebede Y, Mills C. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: Treatment complexity and XDR-TB among treatment failures. Plos One 2007; 2. e1126. doi:10.1371/journal.pone.0001126.
9. Nahar BL, Mosharrof Hossain AKM, Islam MM, Saha DR. A comparative study on the adverse effects of two anti-tuberculosis drugs regimen in initial two-month treatment period. Bangladesh J Pharmacol 2006; 1: 51-7.
10. Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M. Adverse events associated with pyrazinamide and levofloxacin in the treatment of multidrug-resistant tuberculosis. CMAJ 2002; 167: 131-6
11. Furin J J, Mitnick C D, Shin SS, Bayona J, Becerra MC, Singler JM, Alcantara F, Castaneda C, Sanchez E, Acha J, Farmer PE, Kim JY. Ocurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J tuberc Lung Dis 2001; 5: 648-55.
12. Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Mishustin S, Barnashov A, Karpeichik Y, Andreev YG, Golubchikova VT, Tonkel TP, Yanova GV, Yedilbayev A, Rich ML, Mukherjee JS, Furin JJ, Atwood S, Farmer PE, Keshavjee S. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis 2007; 11: 1314-20.
13. Lanternier F, Dalban C, Perez L, Bricaire F, Costagliola D, Caumes E. Tolerability of anti-tuberculosis treatment and HIV serostatus. Int J Tuberc Lung Dis 2007; 11: 1203-9.
14. Bloss E, Kukša L, Holtz T. H., Riekstina V, Skripčonoka V, Kammerer S, Leimane V. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dic 2010; 14: 275-81.
15. Tupasi TE, Gupta R, Quelapio MID, Orillaza RB, Mira NR, Mangubat NV, Belen V, Arnisto N, Macalintal L, Arabit M, Lagahid, JY, Espinal M, Floyd K. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: A cohort study in the Philippines. Plos One 2006; 3: e352. doi: 10.1371/journal.pmed.0030352.
16. Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, Satti H. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. Plos One 2009; 4: e7186. doi: 10.1371/journal.pone.0007186.
17. World Health Organization. Treatment of tuberculosis, 4thed. WHO/HTM/TB/2009.420. Geneva: WHO; 2010.
18. Cain K P, Kanara N, Laserson KF, Vannarith C, Sameourn K, Samnang K, Qualls M L, Wells CD, Varma J K. The epidemiology of HIV-associated tuberculosis in rural Cambodia. Int J Tuberc Lung Dis 2007; 11: 1008-13.
19. de Jager P and van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int JTuberc Lung Dis 2002; 6: 622-7.
20. Duggal P and Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear, Nose and Throat Disorders 2007; 7: doi: 10.1186/1472-6815-7-5.
21. Brummett RE and Fox KE. Aminoglycoside-induced hearing loss in humans. Antimicrobial Agents and Chemotherapy 1989; 33:797-800.
22. Nadol J B. Medical progress: Hearing loss. N Engl J Med 1993; 329: 1092-1102.
23. Tan KHV, Mulheran M, Knox A J, Smyth A R. Aminoglycoside prescribing and surveillance in cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 819-23.
24. Selimoglu E. Aminoglycoside-induced ototoxicity. Current Pharmaceutical Design 2007; 13: 119-26.